Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Trius Therapeutics, Inc.

http://www.triusrx.com/index.php

Latest From Trius Therapeutics, Inc.

Idorsia Asset Sell Off Continues But Future Still Up In The Air

A new outlicensing deal with Viatris will keep it afloat for now but Idorsia needs more time, money and R&D success to secure its long-term future.

Idorsia, Still Facing Cash Crunch, Says Cost-Reduction Effort Will Conclude In 2023

With a commercial product ramping up in the US and EU and three Phase III candidates, Idorsia is burning through cash quickly and needs more remedies beyond its 475-person headcount reduction.

Business Strategies Companies

Additional Analyses Help Idorsia Secure English Funding For Chronic Insomnia Drug Quviviq

Quviviq is to become the first dual orexin receptor antagonist available on the National Health Service. Just over 20,000 people in England could receive treatment with the drug in its first year, says the health technology assessment institute, NICE.

Europe United Kingdom

Johnson & Johnson Gets Its Aprocitentan Money Back

The US company has returned rights to the hypertension product to Idorsia, which was already in the grip of a cash crunch and will now face greater difficulties getting the drug to market. 

Deals Blood & Coagulation Disorders
See All

Company Information

UsernamePublicRestriction

Register